Mon, August 8, 2022
Fri, August 5, 2022
Thu, August 4, 2022

Neena Bitritto-Garg Downgraded (ACAD) to Hold and Decreased Target to $15 on, Aug 5th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. -and-decreased-target-to-15-on-aug-5th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Neena Bitritto-Garg of Citigroup, Downgraded "ACADIA Pharmaceuticals Inc." (ACAD) to Hold and Decreased Target from $19 to $15 on, Aug 5th, 2022.

Neena has made no other calls on ACAD in the last 4 months.



There are 7 other peers that have a rating on ACAD. Out of the 7 peers that are also analyzing ACAD, 3 agree with Neena's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Decreased Target to $22 on, Friday, July 15th, 2022
  • Jay Olson of "Oppenheimer" Maintained at Hold with Decreased Target to $19 on, Tuesday, June 21st, 2022
  • Vamil Divan of "Mizuho" Maintained at Hold with Decreased Target to $27 on, Tuesday, April 19th, 2022


These are the ratings of the 4 analyists that currently disagree with Neena


  • Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $27 on, Monday, July 11th, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $20 on, Tuesday, June 21st, 2022
  • Charles Duncan of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $26 on, Tuesday, June 21st, 2022
  • Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $26 on, Tuesday, June 21st, 2022

Publication Contributing Sources